{"analyses":[{"ciLowerLimit":"0.83","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.22","estimateComment":"Based on a Cox proportional hazards model stratified by the randomization stratification factors; a hazard ratio \\< 1 favors denosumab.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.94","paramType":"Hazard Ratio (HR)","paramValue":"1.01","statisticalComment":"Stratified by breast cancer therapy/LN status, hormone receptor status, HER-2 status, age, and geographic region.","statisticalMethod":"Stratified Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"10.8","value":"9.5"},{"groupId":"OG001","lowerLimit":"8.3","upperLimit":"10.7","value":"9.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2253"},{"groupId":"OG001","value":"2256"}],"units":"Participants"}],"description":"Overall survival (OS) time was defined as the time interval from the randomization date to the date of death from any cause. Participants last known to be alive were censored at their last contact date.\n\nSince the median time to overall survival could not be estimated at the time of the final analysis due to low numbers of events, the percentage of participants with an event (i.e., death) is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to receive placebo subcutaneous injections once every 3 or 4 weeks for approximately 6 months followed by placebo subcutaneous injections once every 3 months for 4.5 years.","id":"OG000","title":"Placebo"},{"description":"Participants were randomized to receive denosumab 120 mg subcutaneous injections once every 3 or 4 weeks for approximately 6 months followed by denosumab 120 mg subcutaneous injections once every 3 months for 4.5 years.","id":"OG001","title":"Denosumab"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization until the end of study; median (minimum, maximum) time on study was 72.7 (0, 92) and 72.3 (0, 92) months in each treatment group respectively.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}